C. J. David and J. L. Manley, Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged, Genes Dev, vol.24, pp.2343-2364, 2010.

S. Germann, L. Gratadou, M. Dutertre, and D. Auboeuf, Splicing programs and cancer, J Nucleic Acids, vol.2012, p.269570, 2012.

M. *3.-danan-gotthold, R. Golan-gerstl, and E. Eisenberg, Identification of recurrent regulated alternative splicing events across human solid tumors, Nucleic Acids Res, 2015.

E. Sebestyen, M. Zawisza, and E. Eyras, Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer, Nucleic Acids Res, vol.43, pp.1345-1356, 2015.

, Based on the RNA-Seq data from the TCGA consortium, these two papers report the first large scale analyses of alternative splicing events occuring in a high number of solid tumors, and identify splicing signatures specific of cancer type or histological sub-type. They provide the rationale for future studies designed for identification of splicing-based diagnostic/prognostic biomarkers and therapeutic targets

Y. S. Tsai, D. Dominguez, and S. M. Gomez, Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors, Oncotarget, vol.6, pp.6825-6839, 2015.

C. M. Misquitta-ali, E. Cheng, and D. O'hanlon, Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer, Mol Cell Biol, vol.31, pp.138-150, 2010.

F. Y. *7.-zong, X. Fu, and W. J. Wei, The RNA-binding protein QKI suppresses cancerassociated aberrant splicing, PLoS Genet, vol.10, p.1004289, 2014.

K. Yoshida, M. Sanada, and Y. Shiraishi, Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.478, pp.64-69, 2011.

M. Imielinski, A. H. Berger, and P. S. Hammerman, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, Cell, vol.150, pp.1107-1120, 2012.

S. L. Maguire, A. Leonidou, and P. Wai, SF3B1 mutations constitute a novel therapeutic target in breast cancer, J Pathol, vol.235, pp.571-580, 2015.

A. N. Brooks, P. S. Choi, and L. De-waal, A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events, PLoS One, vol.9, p.87361, 2014.

C. L. Shirai, J. N. Ley, and B. S. White, Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo, Cancer Cell, vol.27, pp.631-643, 2015.

E. Kim, J. O. Ilagan, and Y. Liang, SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition, Cancer Cell, vol.27, pp.617-630, 2015.

, These two papers provide the first functional characterization of two transgenic mouse models displaying either U2AF1(S34F) or SRSF2(P95H) mutation. They highlight the consequences control alternative splicing, this study adds another level in the interplay between RNA splicing and DNA damage machineries

A. Wojtuszkiewicz, Y. G. Assaraf, and M. J. Maas, Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance, Expert Opin Drug Metab Toxicol, vol.11, pp.673-689, 2014.

S. M. Dehm, mRNA splicing variants: exploiting modularity to outwit cancer therapy

, Cancer Res, vol.73, pp.5309-5314, 2013.

H. Shi, W. Hugo, and X. Kong, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy, Cancer Discov, vol.4, pp.80-93, 2014.

T. Y. Hsu, L. M. Simon, and N. J. Neill, The spliceosome is a therapeutic vulnerability in MYC-driven cancer, Nature, vol.525, pp.384-388, 2015.

S. Araki, R. Dairiki, and Y. Nakayama, Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing, PLoS One, vol.10, p.116929, 2015.

A. Mavrou, K. Brakspear, and M. Hamdollah-zadeh, Serine-arginine protein kinase 1

, SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer, Oncogene, 2014.

P. Wang, Z. Zhou, and A. Hu, Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt, Mol Cell, vol.54, pp.378-391, 2014.

, either oncogenic or tumor suppressive, through its interaction with the AKT phosphatase PHLPP and thus the control of AKT phosphorylation. SRPK1 pharmacological inhibitors are currently in clinical development and have been shown to exert anti-tumor functions in pre-clinical studies